investigator_user investigator user funding collaborators pending menu bell message arrow_up arrow_down filter layers globe marker add arrow close download edit facebook info linkedin minus plus save share search sort twitter remove user-plus user-minus
  • Project leads
  • Collaborators

Validating Syk as a Target for AML Therapy

Kimberly Stegmaier

0 Collaborator(s)

Funding source

National Institutes of Health (NIH)

Related projects

David Marc Weinstock

Polysomy 21 in Acute Lymphoblastic Leukemia

Leukaemia

Reuben Kapur

Role of p21 Activated Kinase in Leukemogenesis

Leukaemia

Hematology and hematologic malignancies

Joseph H Antin

A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCT

Leukaemia

Effie W Petersdorf

Clinical Significance of MHC Haplotypes in HCT

Leukaemia

Bruce R Blazar

Cytotoxic-T-Lymphocyte (CTL) Therapy of Acute Myeloid Leukemia (AML)

Leukaemia

Pathology Hematology and hematologic malignancies

Hongbo Chi

Tsc1/mTOR axis in immune homeostasis and tumorigenesis

Leukaemia

Margaret A Goodell

A Mouse Model of DNMT3A-Associated Hematologic Malignancy

Leukaemia

Zhe Li

IGF/IGF1R signaling in hematopoiesis and leukemogenesis

Leukaemia

Peter Aplan

Collaborative Pathways that Lead to Leukemia

Leukaemia

Pathology Hematology and hematologic malignancies